MB
Therapeutic Areas
United Therapeutics Pipeline
| Drug | Indication | Phase |
|---|---|---|
| Treprostinil (Remodulin) | Pulmonary Arterial Hypertension | Commercial |
| Treprostinil (Tyvaso) | PAH and PH-ILD | Commercial |
| Treprostinil (Orenitram) | Pulmonary Arterial Hypertension | Commercial |
| Selexipag (Uptravi) | Pulmonary Arterial Hypertension | Commercial |
| Ralinepag | Pulmonary Arterial Hypertension | Phase 3 |
| Aurora-GT | AADC Deficiency | Phase 1/2 |
| Xenotransplant Program | Organ Transplantation | Pre-clinical |
| RemUnity Pump | PAH Drug Delivery | Development |
Leadership Team at United Therapeutics
DM
Dr. Martine Rothblatt
Chairman and Chief Executive Officer
JE
James Edgemond
Chief Financial Officer
DL
Dr. Leigh Peterson
Chief Medical Officer
DD
Dr. David Nagle
Chief Technology Officer
PM
Paul McCudden
Chief Commercial Officer
DC
Dr. Christopher Paige
Executive Vice President, Research and Development